nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.112	0.181	CbGbCtD
Pazopanib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0893	0.144	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—ankylosing spondylitis	0.0451	0.0726	CbGbCtD
Pazopanib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0445	0.0718	CbGbCtD
Pazopanib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0425	0.0684	CbGbCtD
Pazopanib—ABCG2—Methotrexate—ankylosing spondylitis	0.0358	0.0577	CbGbCtD
Pazopanib—ABCB1—Betamethasone—ankylosing spondylitis	0.0276	0.0445	CbGbCtD
Pazopanib—ABCB1—Prednisolone—ankylosing spondylitis	0.0272	0.0439	CbGbCtD
Pazopanib—ABCB1—Prednisone—ankylosing spondylitis	0.0257	0.0415	CbGbCtD
Pazopanib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0254	0.041	CbGbCtD
Pazopanib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0237	0.0382	CbGbCtD
Pazopanib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0193	0.0311	CbGbCtD
Pazopanib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0165	0.0267	CbGbCtD
Pazopanib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0163	0.0263	CbGbCtD
Pazopanib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0161	0.0259	CbGbCtD
Pazopanib—CYP3A4—Prednisone—ankylosing spondylitis	0.0154	0.0248	CbGbCtD
Pazopanib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0151	0.0244	CbGbCtD
Pazopanib—ABCB1—Methotrexate—ankylosing spondylitis	0.0129	0.0208	CbGbCtD
Pazopanib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00962	0.0155	CbGbCtD
Pazopanib—FGFR3—cartilage tissue—ankylosing spondylitis	0.00921	0.26	CbGeAlD
Pazopanib—FGF1—cartilage tissue—ankylosing spondylitis	0.00639	0.18	CbGeAlD
Pazopanib—SH2B3—tendon—ankylosing spondylitis	0.00188	0.0531	CbGeAlD
Pazopanib—AURKC—tendon—ankylosing spondylitis	0.00185	0.0522	CbGeAlD
Pazopanib—STK16—tendon—ankylosing spondylitis	0.0016	0.0451	CbGeAlD
Pazopanib—RIOK2—tendon—ankylosing spondylitis	0.00158	0.0444	CbGeAlD
Pazopanib—STK36—tendon—ankylosing spondylitis	0.00142	0.0399	CbGeAlD
Pazopanib—PI4KB—tendon—ankylosing spondylitis	0.00139	0.0393	CbGeAlD
Pazopanib—PIP4K2C—tendon—ankylosing spondylitis	0.00122	0.0345	CbGeAlD
Pazopanib—FGFR1—tendon—ankylosing spondylitis	0.00121	0.0342	CbGeAlD
Pazopanib—FLT1—tendon—ankylosing spondylitis	0.000956	0.027	CbGeAlD
Pazopanib—EPHB6—tendon—ankylosing spondylitis	0.000945	0.0266	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000909	0.105	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000909	0.105	CbGdCrCtD
Pazopanib—STK10—tendon—ankylosing spondylitis	0.000905	0.0255	CbGeAlD
Pazopanib—TAOK3—tendon—ankylosing spondylitis	0.000901	0.0254	CbGeAlD
Pazopanib—PDGFRA—tendon—ankylosing spondylitis	0.000896	0.0253	CbGeAlD
Pazopanib—SH2B3—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000895	0.104	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000895	0.104	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000874	0.101	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000874	0.101	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisone—ankylosing spondylitis	0.00083	0.0961	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisone—ankylosing spondylitis	0.00083	0.0961	CbGdCrCtD
Pazopanib—SH2B3—Betamethasone—Prednisolone—ankylosing spondylitis	0.00081	0.0938	CbGdCrCtD
Pazopanib—SH2B3—Dexamethasone—Prednisolone—ankylosing spondylitis	0.00081	0.0938	CbGdCrCtD
Pazopanib—KDR—tendon—ankylosing spondylitis	0.000808	0.0228	CbGeAlD
Pazopanib—MAP2K5—tendon—ankylosing spondylitis	0.000808	0.0228	CbGeAlD
Pazopanib—CSF1R—tendon—ankylosing spondylitis	0.000789	0.0222	CbGeAlD
Pazopanib—PDGFRB—tendon—ankylosing spondylitis	0.000699	0.0197	CbGeAlD
Pazopanib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000409	0.00204	CcSEcCtD
Pazopanib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000409	0.00204	CcSEcCtD
Pazopanib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000408	0.00204	CcSEcCtD
Pazopanib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000405	0.00202	CcSEcCtD
Pazopanib—Weight decreased—Prednisone—ankylosing spondylitis	0.000403	0.00201	CcSEcCtD
Pazopanib—Vision blurred—Prednisolone—ankylosing spondylitis	0.000402	0.00201	CcSEcCtD
Pazopanib—Liver function test abnormal—Methotrexate—ankylosing spondylitis	0.000397	0.00198	CcSEcCtD
Pazopanib—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.000394	0.00197	CcSEcCtD
Pazopanib—Erythema—Triamcinolone—ankylosing spondylitis	0.000393	0.00196	CcSEcCtD
Pazopanib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000392	0.00195	CcSEcCtD
Pazopanib—Erythema—Methylprednisolone—ankylosing spondylitis	0.000392	0.00195	CcSEcCtD
Pazopanib—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.000391	0.00195	CcSEcCtD
Pazopanib—Myocardial infarction—Prednisone—ankylosing spondylitis	0.000389	0.00194	CcSEcCtD
Pazopanib—Breast disorder—Methotrexate—ankylosing spondylitis	0.000389	0.00194	CcSEcCtD
Pazopanib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000384	0.00192	CcSEcCtD
Pazopanib—Syncope—Prednisolone—ankylosing spondylitis	0.000383	0.00191	CcSEcCtD
Pazopanib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000382	0.00191	CcSEcCtD
Pazopanib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000382	0.00191	CcSEcCtD
Pazopanib—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000375	0.00187	CcSEcCtD
Pazopanib—Angiopathy—Betamethasone—ankylosing spondylitis	0.000371	0.00185	CcSEcCtD
Pazopanib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000371	0.00185	CcSEcCtD
Pazopanib—Hypertension—Prednisolone—ankylosing spondylitis	0.000369	0.00184	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000365	0.00182	CcSEcCtD
Pazopanib—Bradycardia—Prednisone—ankylosing spondylitis	0.000363	0.00181	CcSEcCtD
Pazopanib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000362	0.0018	CcSEcCtD
Pazopanib—Alopecia—Betamethasone—ankylosing spondylitis	0.000362	0.0018	CcSEcCtD
Pazopanib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000358	0.00179	CcSEcCtD
Pazopanib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000356	0.00178	CcSEcCtD
Pazopanib—Erythema—Dexamethasone—ankylosing spondylitis	0.000356	0.00178	CcSEcCtD
Pazopanib—Erythema—Betamethasone—ankylosing spondylitis	0.000356	0.00178	CcSEcCtD
Pazopanib—Syncope—Triamcinolone—ankylosing spondylitis	0.000352	0.00176	CcSEcCtD
Pazopanib—Syncope—Methylprednisolone—ankylosing spondylitis	0.000351	0.00175	CcSEcCtD
Pazopanib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.00035	0.00175	CcSEcCtD
Pazopanib—Oedema—Prednisolone—ankylosing spondylitis	0.000348	0.00174	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—ankylosing spondylitis	0.000348	0.00173	CcSEcCtD
Pazopanib—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000345	0.00172	CcSEcCtD
Pazopanib—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000344	0.00172	CcSEcCtD
Pazopanib—Shock—Prednisolone—ankylosing spondylitis	0.000343	0.00171	CcSEcCtD
Pazopanib—Cough—Triamcinolone—ankylosing spondylitis	0.000343	0.00171	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.00034	0.00169	CcSEcCtD
Pazopanib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000339	0.00169	CcSEcCtD
Pazopanib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000338	0.00169	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.000337	0.00168	CcSEcCtD
Pazopanib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000334	0.00167	CcSEcCtD
Pazopanib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000333	0.00166	CcSEcCtD
Pazopanib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000333	0.00166	CcSEcCtD
Pazopanib—Eye disorder—Prednisone—ankylosing spondylitis	0.000333	0.00166	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000332	0.00165	CcSEcCtD
Pazopanib—Infestation—Methotrexate—ankylosing spondylitis	0.000332	0.00165	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000331	0.00165	CcSEcCtD
Pazopanib—Flushing—Prednisone—ankylosing spondylitis	0.000331	0.00165	CcSEcCtD
Pazopanib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000327	0.00163	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000323	0.00161	CcSEcCtD
Pazopanib—Angiopathy—Prednisone—ankylosing spondylitis	0.000323	0.00161	CcSEcCtD
Pazopanib—Oedema—Triamcinolone—ankylosing spondylitis	0.00032	0.0016	CcSEcCtD
Pazopanib—Syncope—Dexamethasone—ankylosing spondylitis	0.000319	0.00159	CcSEcCtD
Pazopanib—Syncope—Betamethasone—ankylosing spondylitis	0.000319	0.00159	CcSEcCtD
Pazopanib—Infection—Triamcinolone—ankylosing spondylitis	0.000318	0.00159	CcSEcCtD
Pazopanib—Infection—Methylprednisolone—ankylosing spondylitis	0.000318	0.00158	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—ankylosing spondylitis	0.000316	0.00158	CcSEcCtD
Pazopanib—Shock—Triamcinolone—ankylosing spondylitis	0.000315	0.00157	CcSEcCtD
Pazopanib—Insomnia—Prednisolone—ankylosing spondylitis	0.000315	0.00157	CcSEcCtD
Pazopanib—Alopecia—Prednisone—ankylosing spondylitis	0.000315	0.00157	CcSEcCtD
Pazopanib—Shock—Methylprednisolone—ankylosing spondylitis	0.000314	0.00157	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000314	0.00156	CcSEcCtD
Pazopanib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000313	0.00156	CcSEcCtD
Pazopanib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000313	0.00156	CcSEcCtD
Pazopanib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000313	0.00156	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000313	0.00156	CcSEcCtD
Pazopanib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000313	0.00156	CcSEcCtD
Pazopanib—Mental disorder—Prednisone—ankylosing spondylitis	0.000312	0.00156	CcSEcCtD
Pazopanib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00031	0.00155	CcSEcCtD
Pazopanib—Erythema—Prednisone—ankylosing spondylitis	0.00031	0.00155	CcSEcCtD
Pazopanib—Malnutrition—Prednisone—ankylosing spondylitis	0.00031	0.00155	CcSEcCtD
Pazopanib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.00031	0.00154	CcSEcCtD
Pazopanib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000309	0.00154	CcSEcCtD
Pazopanib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000308	0.00153	CcSEcCtD
Pazopanib—Hypertension—Betamethasone—ankylosing spondylitis	0.000308	0.00153	CcSEcCtD
Pazopanib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000303	0.00151	CcSEcCtD
Pazopanib—Myalgia—Betamethasone—ankylosing spondylitis	0.000303	0.00151	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000299	0.00149	CcSEcCtD
Pazopanib—Pain—Prednisolone—ankylosing spondylitis	0.000298	0.00149	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000298	0.00148	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000294	0.00147	CcSEcCtD
Pazopanib—Vision blurred—Prednisone—ankylosing spondylitis	0.000292	0.00146	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000292	0.00146	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000292	0.00146	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000291	0.00145	CcSEcCtD
Pazopanib—Oedema—Dexamethasone—ankylosing spondylitis	0.000291	0.00145	CcSEcCtD
Pazopanib—Oedema—Betamethasone—ankylosing spondylitis	0.000291	0.00145	CcSEcCtD
Pazopanib—Insomnia—Triamcinolone—ankylosing spondylitis	0.00029	0.00144	CcSEcCtD
Pazopanib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000289	0.00144	CcSEcCtD
Pazopanib—Infection—Dexamethasone—ankylosing spondylitis	0.000289	0.00144	CcSEcCtD
Pazopanib—Infection—Betamethasone—ankylosing spondylitis	0.000289	0.00144	CcSEcCtD
Pazopanib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000288	0.00143	CcSEcCtD
Pazopanib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000287	0.00143	CcSEcCtD
Pazopanib—Anaemia—Prednisone—ankylosing spondylitis	0.000287	0.00143	CcSEcCtD
Pazopanib—Shock—Dexamethasone—ankylosing spondylitis	0.000286	0.00143	CcSEcCtD
Pazopanib—Shock—Betamethasone—ankylosing spondylitis	0.000286	0.00143	CcSEcCtD
Pazopanib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000286	0.00142	CcSEcCtD
Pazopanib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000285	0.00142	CcSEcCtD
Pazopanib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000285	0.00142	CcSEcCtD
Pazopanib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000285	0.00142	CcSEcCtD
Pazopanib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000285	0.00142	CcSEcCtD
Pazopanib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000282	0.00141	CcSEcCtD
Pazopanib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000281	0.0014	CcSEcCtD
Pazopanib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000281	0.0014	CcSEcCtD
Pazopanib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000281	0.0014	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000278	0.00139	CcSEcCtD
Pazopanib—Syncope—Prednisone—ankylosing spondylitis	0.000278	0.00139	CcSEcCtD
Pazopanib—Anorexia—Betamethasone—ankylosing spondylitis	0.000277	0.00138	CcSEcCtD
Pazopanib—Anorexia—Dexamethasone—ankylosing spondylitis	0.000277	0.00138	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000276	0.00138	CcSEcCtD
Pazopanib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000276	0.00138	CcSEcCtD
Pazopanib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000276	0.00137	CcSEcCtD
Pazopanib—Pain—Triamcinolone—ankylosing spondylitis	0.000274	0.00137	CcSEcCtD
Pazopanib—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000273	0.00136	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—ankylosing spondylitis	0.00027	0.00135	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000268	0.00134	CcSEcCtD
Pazopanib—Hypertension—Prednisone—ankylosing spondylitis	0.000268	0.00134	CcSEcCtD
Pazopanib—Chills—Methotrexate—ankylosing spondylitis	0.000267	0.00133	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000265	0.00132	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000265	0.00132	CcSEcCtD
Pazopanib—Myalgia—Prednisone—ankylosing spondylitis	0.000264	0.00132	CcSEcCtD
Pazopanib—Arthralgia—Prednisone—ankylosing spondylitis	0.000264	0.00132	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—ankylosing spondylitis	0.000263	0.00131	CcSEcCtD
Pazopanib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000263	0.00131	CcSEcCtD
Pazopanib—Insomnia—Betamethasone—ankylosing spondylitis	0.000263	0.00131	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000262	0.00131	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000261	0.0013	CcSEcCtD
Pazopanib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000261	0.0013	CcSEcCtD
Pazopanib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000261	0.0013	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000261	0.0013	CcSEcCtD
Pazopanib—Erythema—Methotrexate—ankylosing spondylitis	0.000259	0.00129	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000259	0.00129	CcSEcCtD
Pazopanib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000256	0.00128	CcSEcCtD
Pazopanib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000256	0.00128	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000254	0.00127	CcSEcCtD
Pazopanib—Oedema—Prednisone—ankylosing spondylitis	0.000253	0.00126	CcSEcCtD
Pazopanib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000253	0.00126	CcSEcCtD
Pazopanib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000253	0.00126	CcSEcCtD
Pazopanib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000253	0.00126	CcSEcCtD
Pazopanib—Infection—Prednisone—ankylosing spondylitis	0.000251	0.00125	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000251	0.00125	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000251	0.00125	CcSEcCtD
Pazopanib—Fatigue—Betamethasone—ankylosing spondylitis	0.000251	0.00125	CcSEcCtD
Pazopanib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000251	0.00125	CcSEcCtD
Pazopanib—Shock—Prednisone—ankylosing spondylitis	0.000249	0.00124	CcSEcCtD
Pazopanib—Pain—Betamethasone—ankylosing spondylitis	0.000249	0.00124	CcSEcCtD
Pazopanib—Pain—Dexamethasone—ankylosing spondylitis	0.000249	0.00124	CcSEcCtD
Pazopanib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000248	0.00124	CcSEcCtD
Pazopanib—Skin disorder—Prednisone—ankylosing spondylitis	0.000246	0.00123	CcSEcCtD
Pazopanib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000245	0.00122	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000244	0.00122	CcSEcCtD
Pazopanib—Anorexia—Prednisone—ankylosing spondylitis	0.000241	0.0012	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—ankylosing spondylitis	0.00024	0.00119	CcSEcCtD
Pazopanib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000238	0.00119	CcSEcCtD
Pazopanib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000238	0.00119	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000232	0.00116	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000231	0.00115	CcSEcCtD
Pazopanib—Dizziness—Prednisolone—ankylosing spondylitis	0.00023	0.00115	CcSEcCtD
Pazopanib—Asthenia—Triamcinolone—ankylosing spondylitis	0.00023	0.00115	CcSEcCtD
Pazopanib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00023	0.00115	CcSEcCtD
Pazopanib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00023	0.00115	CcSEcCtD
Pazopanib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000229	0.00114	CcSEcCtD
Pazopanib—Insomnia—Prednisone—ankylosing spondylitis	0.000229	0.00114	CcSEcCtD
Pazopanib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000227	0.00113	CcSEcCtD
Pazopanib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000227	0.00113	CcSEcCtD
Pazopanib—Cough—Methotrexate—ankylosing spondylitis	0.000226	0.00113	CcSEcCtD
Pazopanib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000226	0.00113	CcSEcCtD
Pazopanib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000223	0.00111	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—ankylosing spondylitis	0.000221	0.0011	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—ankylosing spondylitis	0.000221	0.0011	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000221	0.0011	CcSEcCtD
Pazopanib—Decreased appetite—Prednisone—ankylosing spondylitis	0.00022	0.0011	CcSEcCtD
Pazopanib—Rash—Prednisolone—ankylosing spondylitis	0.00022	0.0011	CcSEcCtD
Pazopanib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000219	0.00109	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000219	0.00109	CcSEcCtD
Pazopanib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000219	0.00109	CcSEcCtD
Pazopanib—Fatigue—Prednisone—ankylosing spondylitis	0.000218	0.00109	CcSEcCtD
Pazopanib—Headache—Prednisolone—ankylosing spondylitis	0.000218	0.00109	CcSEcCtD
Pazopanib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000212	0.00106	CcSEcCtD
Pazopanib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000211	0.00105	CcSEcCtD
Pazopanib—Infection—Methotrexate—ankylosing spondylitis	0.00021	0.00105	CcSEcCtD
Pazopanib—Asthenia—Betamethasone—ankylosing spondylitis	0.000209	0.00104	CcSEcCtD
Pazopanib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000209	0.00104	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000207	0.00103	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000207	0.00103	CcSEcCtD
Pazopanib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000207	0.00103	CcSEcCtD
Pazopanib—Nausea—Prednisolone—ankylosing spondylitis	0.000207	0.00103	CcSEcCtD
Pazopanib—Pruritus—Betamethasone—ankylosing spondylitis	0.000206	0.00103	CcSEcCtD
Pazopanib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000206	0.00103	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000205	0.00102	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000205	0.00102	CcSEcCtD
Pazopanib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000204	0.00102	CcSEcCtD
Pazopanib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000203	0.00101	CcSEcCtD
Pazopanib—Rash—Triamcinolone—ankylosing spondylitis	0.000202	0.00101	CcSEcCtD
Pazopanib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000202	0.00101	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—ankylosing spondylitis	0.000202	0.00101	CcSEcCtD
Pazopanib—Rash—Methylprednisolone—ankylosing spondylitis	0.000202	0.00101	CcSEcCtD
Pazopanib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000201	0.001	CcSEcCtD
Pazopanib—Headache—Triamcinolone—ankylosing spondylitis	0.000201	0.001	CcSEcCtD
Pazopanib—Headache—Methylprednisolone—ankylosing spondylitis	0.0002	0.000999	CcSEcCtD
Pazopanib—Abdominal pain—Prednisone—ankylosing spondylitis	0.0002	0.000998	CcSEcCtD
Pazopanib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000199	0.000992	CcSEcCtD
Pazopanib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000199	0.000992	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000193	0.000961	CcSEcCtD
Pazopanib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000192	0.000959	CcSEcCtD
Pazopanib—Dizziness—Betamethasone—ankylosing spondylitis	0.000192	0.000959	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—ankylosing spondylitis	0.000191	0.000954	CcSEcCtD
Pazopanib—Nausea—Triamcinolone—ankylosing spondylitis	0.00019	0.000949	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.00019	0.000947	CcSEcCtD
Pazopanib—Nausea—Methylprednisolone—ankylosing spondylitis	0.00019	0.000947	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000189	0.000941	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—ankylosing spondylitis	0.000188	0.000938	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000186	0.000929	CcSEcCtD
Pazopanib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000185	0.000922	CcSEcCtD
Pazopanib—Vomiting—Betamethasone—ankylosing spondylitis	0.000185	0.000922	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000184	0.000917	CcSEcCtD
Pazopanib—Rash—Dexamethasone—ankylosing spondylitis	0.000183	0.000914	CcSEcCtD
Pazopanib—Rash—Betamethasone—ankylosing spondylitis	0.000183	0.000914	CcSEcCtD
Pazopanib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000183	0.000913	CcSEcCtD
Pazopanib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000183	0.000913	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000183	0.000911	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—ankylosing spondylitis	0.000182	0.00091	CcSEcCtD
Pazopanib—Headache—Dexamethasone—ankylosing spondylitis	0.000182	0.000908	CcSEcCtD
Pazopanib—Headache—Betamethasone—ankylosing spondylitis	0.000182	0.000908	CcSEcCtD
Pazopanib—Asthenia—Prednisone—ankylosing spondylitis	0.000182	0.000906	CcSEcCtD
Pazopanib—Pain—Methotrexate—ankylosing spondylitis	0.000181	0.000902	CcSEcCtD
Pazopanib—Pruritus—Prednisone—ankylosing spondylitis	0.000179	0.000893	CcSEcCtD
Pazopanib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000173	0.000864	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000173	0.000863	CcSEcCtD
Pazopanib—Nausea—Betamethasone—ankylosing spondylitis	0.000173	0.000861	CcSEcCtD
Pazopanib—Nausea—Dexamethasone—ankylosing spondylitis	0.000173	0.000861	CcSEcCtD
Pazopanib—Dizziness—Prednisone—ankylosing spondylitis	0.000167	0.000835	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000167	0.000834	CcSEcCtD
Pazopanib—FGFR2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000164	0.00122	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000162	0.0012	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—ERAP1—ankylosing spondylitis	0.000162	0.0012	CbGpPWpGaD
Pazopanib—ITK—Immune System—IL1A—ankylosing spondylitis	0.000161	0.0012	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000161	0.0012	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—ERAP1—ankylosing spondylitis	0.000161	0.00119	CbGpPWpGaD
Pazopanib—Vomiting—Prednisone—ankylosing spondylitis	0.000161	0.000803	CcSEcCtD
Pazopanib—ITK—Immune System—CD40LG—ankylosing spondylitis	0.00016	0.00119	CbGpPWpGaD
Pazopanib—Rash—Prednisone—ankylosing spondylitis	0.00016	0.000796	CcSEcCtD
Pazopanib—Dermatitis—Prednisone—ankylosing spondylitis	0.000159	0.000795	CcSEcCtD
Pazopanib—FGFR1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000159	0.00118	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HLA-C—ankylosing spondylitis	0.000159	0.00118	CbGpPWpGaD
Pazopanib—Headache—Prednisone—ankylosing spondylitis	0.000159	0.000791	CcSEcCtD
Pazopanib—FGFR2—Immune System—CARD9—ankylosing spondylitis	0.000158	0.00118	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000156	0.00116	CbGpPWpGaD
Pazopanib—KIT—Immune System—CARD9—ankylosing spondylitis	0.000156	0.00115	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1R2—ankylosing spondylitis	0.000153	0.00114	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000153	0.00113	CbGpPWpGaD
Pazopanib—ITK—Immune System—HLA-B—ankylosing spondylitis	0.000153	0.00113	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000153	0.00113	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000152	0.00113	CbGpPWpGaD
Pazopanib—Asthenia—Methotrexate—ankylosing spondylitis	0.000152	0.000757	CcSEcCtD
Pazopanib—FGF1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000151	0.00112	CbGpPWpGaD
Pazopanib—Nausea—Prednisone—ankylosing spondylitis	0.00015	0.00075	CcSEcCtD
Pazopanib—FGF1—Disease—B3GNT2—ankylosing spondylitis	0.00015	0.00112	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1R2—ankylosing spondylitis	0.00015	0.00111	CbGpPWpGaD
Pazopanib—Pruritus—Methotrexate—ankylosing spondylitis	0.00015	0.000746	CcSEcCtD
Pazopanib—FGFR3—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000148	0.0011	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000148	0.0011	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CARD9—ankylosing spondylitis	0.000148	0.0011	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CARD9—ankylosing spondylitis	0.000147	0.00109	CbGpPWpGaD
Pazopanib—FGFR3—Innate Immune System—HLA-B—ankylosing spondylitis	0.000147	0.00109	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—ERAP1—ankylosing spondylitis	0.000145	0.00108	CbGpPWpGaD
Pazopanib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000145	0.000722	CcSEcCtD
Pazopanib—FGFR3—Immune System—HLA-C—ankylosing spondylitis	0.000145	0.00107	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HLA-C—ankylosing spondylitis	0.000143	0.00106	CbGpPWpGaD
Pazopanib—LYN—Immune System—ERAP1—ankylosing spondylitis	0.000142	0.00105	CbGpPWpGaD
Pazopanib—LCK—Disease—ANTXR2—ankylosing spondylitis	0.000142	0.00105	CbGpPWpGaD
Pazopanib—ITK—Immune System—HLA-A—ankylosing spondylitis	0.000141	0.00105	CbGpPWpGaD
Pazopanib—FGFR3—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000141	0.00105	CbGpPWpGaD
Pazopanib—MAP2K5—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000141	0.00105	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HLA-C—ankylosing spondylitis	0.00014	0.00104	CbGpPWpGaD
Pazopanib—Dizziness—Methotrexate—ankylosing spondylitis	0.00014	0.000698	CcSEcCtD
Pazopanib—LCK—HIV Infection—HLA-A—ankylosing spondylitis	0.000138	0.00102	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000137	0.00102	CbGpPWpGaD
Pazopanib—LYN—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000137	0.00102	CbGpPWpGaD
Pazopanib—ITK—Immune System—CRP—ankylosing spondylitis	0.000135	0.001	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000135	0.000998	CbGpPWpGaD
Pazopanib—Vomiting—Methotrexate—ankylosing spondylitis	0.000135	0.000671	CcSEcCtD
Pazopanib—Rash—Methotrexate—ankylosing spondylitis	0.000133	0.000665	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000133	0.000665	CcSEcCtD
Pazopanib—PDGFRB—Immune System—CARD9—ankylosing spondylitis	0.000133	0.000985	CbGpPWpGaD
Pazopanib—Headache—Methotrexate—ankylosing spondylitis	0.000133	0.000661	CcSEcCtD
Pazopanib—FGFR3—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000131	0.00097	CbGpPWpGaD
Pazopanib—LYN—Immune System—CARD9—ankylosing spondylitis	0.00013	0.000964	CbGpPWpGaD
Pazopanib—FGFR3—Innate Immune System—CRP—ankylosing spondylitis	0.00013	0.000963	CbGpPWpGaD
Pazopanib—ITK—Immune System—TLR4—ankylosing spondylitis	0.000129	0.000959	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000128	0.00095	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL1RN—ankylosing spondylitis	0.000126	0.000932	CbGpPWpGaD
Pazopanib—Nausea—Methotrexate—ankylosing spondylitis	0.000126	0.000627	CcSEcCtD
Pazopanib—FGFR2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000125	0.000928	CbGpPWpGaD
Pazopanib—FGFR3—Innate Immune System—TLR4—ankylosing spondylitis	0.000125	0.000923	CbGpPWpGaD
Pazopanib—FGFR2—Disease—B3GNT2—ankylosing spondylitis	0.000124	0.000923	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000123	0.000914	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000123	0.000912	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1R2—ankylosing spondylitis	0.000123	0.000911	CbGpPWpGaD
Pazopanib—KIT—Disease—B3GNT2—ankylosing spondylitis	0.000122	0.000906	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000122	0.000906	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000121	0.000898	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-C—ankylosing spondylitis	0.00012	0.000892	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—MMP3—ankylosing spondylitis	0.000119	0.00088	CbGpPWpGaD
Pazopanib—FGF1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000118	0.000878	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000117	0.00087	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000117	0.000865	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERAP1—ankylosing spondylitis	0.000116	0.000864	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000116	0.000863	CbGpPWpGaD
Pazopanib—FGFR1—Disease—B3GNT2—ankylosing spondylitis	0.000116	0.00086	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—B3GNT2—ankylosing spondylitis	0.000116	0.000858	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HLA-C—ankylosing spondylitis	0.000115	0.000852	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000114	0.000844	CbGpPWpGaD
Pazopanib—LCK—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000112	0.000832	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—CD79A—ankylosing spondylitis	0.00011	0.000819	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.00011	0.000818	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000109	0.000806	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—MMP3—ankylosing spondylitis	0.000109	0.000805	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—CRP—ankylosing spondylitis	0.000108	0.000801	CbGpPWpGaD
Pazopanib—LCK—Immune System—CARD9—ankylosing spondylitis	0.000107	0.00079	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000105	0.000777	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL1RN—ankylosing spondylitis	0.000104	0.000775	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—B3GNT2—ankylosing spondylitis	0.000104	0.000773	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—TLR4—ankylosing spondylitis	0.000103	0.000767	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000103	0.000761	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000102	0.000757	CbGpPWpGaD
Pazopanib—FGFR1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000101	0.00075	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000101	0.00075	CbGpPWpGaD
Pazopanib—LIMK2—Developmental Biology—TNF—ankylosing spondylitis	0.000101	0.000749	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.0001	0.000743	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-C—ankylosing spondylitis	9.95e-05	0.000738	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—HLA-B—ankylosing spondylitis	9.92e-05	0.000736	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-C—ankylosing spondylitis	9.77e-05	0.000725	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.7e-05	0.00072	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.53e-05	0.000707	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—CD40LG—ankylosing spondylitis	9.51e-05	0.000705	CbGpPWpGaD
Pazopanib—EPHB6—Developmental Biology—TNF—ankylosing spondylitis	9.49e-05	0.000704	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—CD40LG—ankylosing spondylitis	9.48e-05	0.000703	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—HLA-B—ankylosing spondylitis	9.42e-05	0.000699	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—HLA-B—ankylosing spondylitis	9.39e-05	0.000697	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-C—ankylosing spondylitis	9.28e-05	0.000688	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-C—ankylosing spondylitis	9.25e-05	0.000686	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CD79A—ankylosing spondylitis	9.17e-05	0.00068	CbGpPWpGaD
Pazopanib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	9.13e-05	0.000677	CbGpPWpGaD
Pazopanib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	9.1e-05	0.000675	CbGpPWpGaD
Pazopanib—PDGFRB—MAPK Signaling Pathway—TNF—ankylosing spondylitis	9.09e-05	0.000674	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—IL1A—ankylosing spondylitis	9.05e-05	0.000671	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.04e-05	0.000671	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HLA-B—ankylosing spondylitis	9.02e-05	0.000669	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—CD40LG—ankylosing spondylitis	9e-05	0.000667	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.99e-05	0.000667	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—CRP—ankylosing spondylitis	8.93e-05	0.000663	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.83e-05	0.000655	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—CRP—ankylosing spondylitis	8.77e-05	0.000651	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PTGER4—ankylosing spondylitis	8.69e-05	0.000644	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL1RN—ankylosing spondylitis	8.65e-05	0.000641	CbGpPWpGaD
Pazopanib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	8.59e-05	0.000637	CbGpPWpGaD
Pazopanib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	8.59e-05	0.000637	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—TLR4—ankylosing spondylitis	8.56e-05	0.000635	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HLA-B—ankylosing spondylitis	8.56e-05	0.000635	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.54e-05	0.000634	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL1RN—ankylosing spondylitis	8.49e-05	0.00063	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—HLA-B—ankylosing spondylitis	8.46e-05	0.000628	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—CD79A—ankylosing spondylitis	8.41e-05	0.000624	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—TLR4—ankylosing spondylitis	8.41e-05	0.000624	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.38e-05	0.000622	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—CD40LG—ankylosing spondylitis	8.37e-05	0.00062	CbGpPWpGaD
Pazopanib—LCK—Disease—B3GNT2—ankylosing spondylitis	8.36e-05	0.00062	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—HLA-A—ankylosing spondylitis	8.36e-05	0.00062	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-C—ankylosing spondylitis	8.34e-05	0.000618	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—CRP—ankylosing spondylitis	8.33e-05	0.000617	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—CRP—ankylosing spondylitis	8.3e-05	0.000616	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—HLA-B—ankylosing spondylitis	8.29e-05	0.000615	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-C—ankylosing spondylitis	8.16e-05	0.000605	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-B—ankylosing spondylitis	8.13e-05	0.000603	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—MMP3—ankylosing spondylitis	8.1e-05	0.000601	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL1RN—ankylosing spondylitis	8.06e-05	0.000598	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL1RN—ankylosing spondylitis	8.04e-05	0.000596	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—B3GNT2—ankylosing spondylitis	8e-05	0.000593	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—TLR4—ankylosing spondylitis	7.98e-05	0.000592	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—TLR4—ankylosing spondylitis	7.96e-05	0.00059	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.96e-05	0.00059	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—HLA-A—ankylosing spondylitis	7.93e-05	0.000588	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PTGER4—ankylosing spondylitis	7.77e-05	0.000576	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CD79A—ankylosing spondylitis	7.59e-05	0.000563	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PTGER4—ankylosing spondylitis	7.57e-05	0.000561	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—CRP—ankylosing spondylitis	7.56e-05	0.000561	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.53e-05	0.000559	CbGpPWpGaD
Pazopanib—FGF1—Immune System—IL1A—ankylosing spondylitis	7.52e-05	0.000558	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—CRP—ankylosing spondylitis	7.48e-05	0.000555	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CD40LG—ankylosing spondylitis	7.48e-05	0.000555	CbGpPWpGaD
Pazopanib—KIT—Immune System—CD79A—ankylosing spondylitis	7.45e-05	0.000553	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—HLA-A—ankylosing spondylitis	7.37e-05	0.000547	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—B3GNT2—ankylosing spondylitis	7.33e-05	0.000543	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—CRP—ankylosing spondylitis	7.32e-05	0.000543	CbGpPWpGaD
Pazopanib—FGFR3—Disease—HLA-A—ankylosing spondylitis	7.32e-05	0.000543	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—TLR4—ankylosing spondylitis	7.25e-05	0.000538	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1RN—ankylosing spondylitis	7.24e-05	0.000537	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PTGER4—ankylosing spondylitis	7.22e-05	0.000536	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—TLR4—ankylosing spondylitis	7.17e-05	0.000532	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-B—ankylosing spondylitis	7.11e-05	0.000527	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1RN—ankylosing spondylitis	7.09e-05	0.000526	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD79A—ankylosing spondylitis	7.07e-05	0.000525	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD79A—ankylosing spondylitis	7.06e-05	0.000523	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—TLR4—ankylosing spondylitis	7.02e-05	0.000521	CbGpPWpGaD
Pazopanib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	6.98e-05	0.000518	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—CD40LG—ankylosing spondylitis	6.86e-05	0.000509	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—HLA-B—ankylosing spondylitis	6.79e-05	0.000504	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	6.78e-05	0.000503	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-C—ankylosing spondylitis	6.69e-05	0.000496	CbGpPWpGaD
Pazopanib—FGF1—Immune System—HLA-A—ankylosing spondylitis	6.59e-05	0.000489	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-B—ankylosing spondylitis	6.52e-05	0.000484	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD79A—ankylosing spondylitis	6.36e-05	0.000472	CbGpPWpGaD
Pazopanib—FGF1—Immune System—CRP—ankylosing spondylitis	6.29e-05	0.000466	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD79A—ankylosing spondylitis	6.22e-05	0.000462	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—IL1A—ankylosing spondylitis	6.22e-05	0.000462	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CD40LG—ankylosing spondylitis	6.19e-05	0.000459	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MMP3—ankylosing spondylitis	6.19e-05	0.000459	CbGpPWpGaD
Pazopanib—KIT—Immune System—IL1A—ankylosing spondylitis	6.11e-05	0.000453	CbGpPWpGaD
Pazopanib—FGF1—Disease—HLA-A—ankylosing spondylitis	6.08e-05	0.000451	CbGpPWpGaD
Pazopanib—KIT—Immune System—CD40LG—ankylosing spondylitis	6.08e-05	0.000451	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.04e-05	0.000448	CbGpPWpGaD
Pazopanib—FGF1—Immune System—TLR4—ankylosing spondylitis	6.03e-05	0.000447	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—CRP—ankylosing spondylitis	6e-05	0.000445	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTGER4—ankylosing spondylitis	5.98e-05	0.000443	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-B—ankylosing spondylitis	5.89e-05	0.000437	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTGER4—ankylosing spondylitis	5.87e-05	0.000435	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1RN—ankylosing spondylitis	5.81e-05	0.000431	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—IL1A—ankylosing spondylitis	5.8e-05	0.00043	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—TNF—ankylosing spondylitis	5.8e-05	0.00043	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—IL1A—ankylosing spondylitis	5.79e-05	0.000429	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-B—ankylosing spondylitis	5.78e-05	0.000429	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CD40LG—ankylosing spondylitis	5.77e-05	0.000428	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—TLR4—ankylosing spondylitis	5.76e-05	0.000427	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CD40LG—ankylosing spondylitis	5.75e-05	0.000427	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTGER4—ankylosing spondylitis	5.57e-05	0.000413	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTGER4—ankylosing spondylitis	5.56e-05	0.000412	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MMP3—ankylosing spondylitis	5.53e-05	0.00041	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-B—ankylosing spondylitis	5.49e-05	0.000407	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-B—ankylosing spondylitis	5.47e-05	0.000406	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—HLA-A—ankylosing spondylitis	5.45e-05	0.000404	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MMP3—ankylosing spondylitis	5.39e-05	0.0004	CbGpPWpGaD
Pazopanib—KIT—Immune System—HLA-A—ankylosing spondylitis	5.36e-05	0.000397	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—IL1A—ankylosing spondylitis	5.21e-05	0.000387	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—CRP—ankylosing spondylitis	5.2e-05	0.000386	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CD40LG—ankylosing spondylitis	5.18e-05	0.000384	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MMP3—ankylosing spondylitis	5.14e-05	0.000381	CbGpPWpGaD
Pazopanib—KIT—Immune System—CRP—ankylosing spondylitis	5.11e-05	0.000379	CbGpPWpGaD
Pazopanib—LYN—Immune System—IL1A—ankylosing spondylitis	5.1e-05	0.000379	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD79A—ankylosing spondylitis	5.1e-05	0.000378	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—HLA-A—ankylosing spondylitis	5.08e-05	0.000377	CbGpPWpGaD
Pazopanib—LYN—Immune System—CD40LG—ankylosing spondylitis	5.07e-05	0.000376	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—HLA-A—ankylosing spondylitis	5.07e-05	0.000376	CbGpPWpGaD
Pazopanib—FGFR2—Disease—HLA-A—ankylosing spondylitis	5.03e-05	0.000373	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTGER4—ankylosing spondylitis	5.01e-05	0.000371	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—TLR4—ankylosing spondylitis	4.99e-05	0.00037	CbGpPWpGaD
Pazopanib—KIT—Disease—HLA-A—ankylosing spondylitis	4.94e-05	0.000367	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-B—ankylosing spondylitis	4.93e-05	0.000366	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTGER4—ankylosing spondylitis	4.9e-05	0.000363	CbGpPWpGaD
Pazopanib—KIT—Immune System—TLR4—ankylosing spondylitis	4.9e-05	0.000363	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—CRP—ankylosing spondylitis	4.85e-05	0.00036	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—CRP—ankylosing spondylitis	4.84e-05	0.000359	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-B—ankylosing spondylitis	4.83e-05	0.000358	CbGpPWpGaD
Pazopanib—FGFR1—Disease—HLA-A—ankylosing spondylitis	4.69e-05	0.000348	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—HLA-A—ankylosing spondylitis	4.68e-05	0.000347	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—TLR4—ankylosing spondylitis	4.65e-05	0.000345	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—TLR4—ankylosing spondylitis	4.64e-05	0.000344	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—HLA-A—ankylosing spondylitis	4.57e-05	0.000339	CbGpPWpGaD
Pazopanib—LYN—Immune System—HLA-A—ankylosing spondylitis	4.47e-05	0.000332	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CRP—ankylosing spondylitis	4.36e-05	0.000323	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—TNF—ankylosing spondylitis	4.27e-05	0.000317	CbGpPWpGaD
Pazopanib—LYN—Immune System—CRP—ankylosing spondylitis	4.27e-05	0.000316	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MMP3—ankylosing spondylitis	4.26e-05	0.000316	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—HLA-A—ankylosing spondylitis	4.22e-05	0.000313	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	4.21e-05	0.000312	CbGpPWpGaD
Pazopanib—LCK—Immune System—IL1A—ankylosing spondylitis	4.18e-05	0.00031	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MMP3—ankylosing spondylitis	4.18e-05	0.00031	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—TLR4—ankylosing spondylitis	4.18e-05	0.00031	CbGpPWpGaD
Pazopanib—LCK—Immune System—CD40LG—ankylosing spondylitis	4.16e-05	0.000308	CbGpPWpGaD
Pazopanib—LYN—Immune System—TLR4—ankylosing spondylitis	4.09e-05	0.000303	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTGER4—ankylosing spondylitis	4.02e-05	0.000298	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MMP3—ankylosing spondylitis	3.97e-05	0.000294	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-B—ankylosing spondylitis	3.96e-05	0.000293	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MMP3—ankylosing spondylitis	3.96e-05	0.000293	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—TNF—ankylosing spondylitis	3.75e-05	0.000278	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.67e-05	0.000272	CbGpPWpGaD
Pazopanib—LCK—Immune System—HLA-A—ankylosing spondylitis	3.67e-05	0.000272	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MMP3—ankylosing spondylitis	3.56e-05	0.000264	CbGpPWpGaD
Pazopanib—LCK—Immune System—CRP—ankylosing spondylitis	3.5e-05	0.000259	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MMP3—ankylosing spondylitis	3.49e-05	0.000259	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	3.46e-05	0.000256	CbGpPWpGaD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.45e-05	0.000256	CbGpPWpGaD
Pazopanib—LCK—Disease—HLA-A—ankylosing spondylitis	3.38e-05	0.000251	CbGpPWpGaD
Pazopanib—LCK—Immune System—TLR4—ankylosing spondylitis	3.35e-05	0.000249	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	2.93e-05	0.000217	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MMP3—ankylosing spondylitis	2.86e-05	0.000212	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.26e-05	0.000168	CbGpPWpGaD
